<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mvjr</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский вестник Юга России</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Herald of the South of Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-8075</issn><issn pub-type="epub">2618-7876</issn><publisher><publisher-name>The Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2219-8075-2024-15-4-72-78</article-id><article-id custom-type="elpub" pub-id-type="custom">mvjr-1945</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>3.1.22 ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>3.1.22 INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Адъювантная активность глюкозоминилмурамилдипептида и перспективы его использования для лечения и профилактики инфекционных болезней</article-title><trans-title-group xml:lang="en"><trans-title>Adjuvant activity of glucosaminylmuramyldipeptide and prospects of its use for the treatment and prevention of infectious diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1103-4244</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филиппенко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Filippenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Филиппенко Анна Владимировна, младший научный сотрудник лаборатории иммунологии</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Anna V. Filippenko, junior Researcher, Laboratory of Immunology</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">filippenko_av@antiplague.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7068-4071</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иванова Инна Александровна, к.б.н., ведущий научный сотрудник, и.о. зав. лабораторией иммунологии</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Inna A. Ivanova, Cand. Sci. (Bio), Leading Researcher Acting Head of the Laboratory Immunology</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">ivanova_ia@antiplague.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5208-7724</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Омельченко</surname><given-names>Н. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Omelchenko</surname><given-names>N. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Омельченко Наталья Дмитриевна, к.м.н., старший научный сотрудник лаборатории иммунологии</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Natalia D. Omelchenko, Cand. Sci. (Med.), Senior Researcher Laboratory of Immunology</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">natalya.omelchenko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4770-5994</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Труфанова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Trufanova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Труфанова Анастасия Александровна, младший научный сотрудник лаборатории иммунологии</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Anastasia A. Trufanova, junior Researcher, Laboratory of Immunology</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">nastyasia61@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский-на-Дону противочумный институт Роспотребнадзора</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><volume>15</volume><issue>4</issue><fpage>72</fpage><lpage>78</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Филиппенко А.В., Иванова И.А., Омельченко Н.Д., Труфанова А.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Филиппенко А.В., Иванова И.А., Омельченко Н.Д., Труфанова А.А.</copyright-holder><copyright-holder xml:lang="en">Filippenko A.V., Ivanova I.A., Omelchenko N.D., Trufanova A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medicalherald.ru/jour/article/view/1945">https://www.medicalherald.ru/jour/article/view/1945</self-uri><abstract><p>Целью обзора являлся анализ литературных данных по влиянию глюкозоминилмурамилдипептида (ГМДП) на факторы врождённого и адаптивного иммунитета при лечении и профилактики различных инфекционных болезней. В задачи обзора входило изучение исследований, проведённых за последние 20 лет и касающихся использования ГМДП для лечения и профилактики инфекционных заболеваний различной этиологии. Поиск литературы осуществлялся базах данных «РИНЦ», «eLibrary», «MedLine». В качестве поисковых слов были задействованы «мурамилдипептид», «механизм действия мурамилдипептида», «глюкозоминилмурамилдипептид для лечения инфекционных болезней», «глюкозоминилмурамилдипептид для профилактики инфекционных болезней», «глюкозоминилмурамилдипептид как адъювант». ГМДП является активатором врождённого и приобретённого иммунитета, усиливает защиту организма от вирусных, бактериальных и грибковых инфекций, а также оказывает адьювантный эффект в развитии поствакцинального иммунного ответа, что определяет перспективность его дальнейшего использования для совершенствования схем лечения и специфической профилактики различных инфекционных болезней.</p></abstract><trans-abstract xml:lang="en"><p>The purpose of the review was to analyze the literature data on the eﬀect of glucosominylmuramyldipeptide on factors of innate and adaptive immunity in the treatment and prevention of various infectious diseases. The purpose of the review was to examine studies conducted over the past 20 years concerning the use of GMDP for the treatment and prevention of infectious diseases of various etiologies. The literature was searched using databases such as RSCI, eLibrary, MedLine. The following search words were used: muramyldipeptide, muramyldipeptide mechanism of action, glucosominylmuramyldipeptide for the treatment of infectious diseases, glucosominylmuramyldipeptide for the prevention of infectious diseases, glucosominylmuramyldipeptide as an adjuvant. GMDP is an activator of innate and acquired immunity, strengthens the body's protection against viral, bacterial and fungal infections, and also has an adjuvant eﬀect in the development of a post-vaccination immune response, which determines the prospects for its further use to improve treatment regimens and speciﬁc prevention of various infectious diseases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>обзор</kwd><kwd>глюкозоминилмурамилдипептид</kwd><kwd>адъювант</kwd><kwd>иммуномодулятор</kwd><kwd>лечение и профилактика инфекций</kwd></kwd-group><kwd-group xml:lang="en"><kwd>review</kwd><kwd>glucosominylmuramyldipeptide</kwd><kwd>adjuvant</kwd><kwd>immunomodulator</kwd><kwd>treatment and prevention of infections</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kitaura H, Ishida M, Kimura K, Sugisawa H, Kishikawa A, et al. Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity. Anal Cell Pathol (Amst). 2018;2018:8047610. https://doi.org/10.1155/2018/8047610</mixed-citation><mixed-citation xml:lang="en">Kitaura H, Ishida M, Kimura K, Sugisawa H, Kishikawa A, et al. Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity. Anal Cell Pathol (Amst). 2018;2018:8047610. https://doi.org/10.1155/2018/8047610</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Козлов И.Г., Тимаков М.А. Иммунотерапия: вчера, сегодня, завтра. Педиатрия. Журнал им. Г.Н. Сперанского. 2009;87(4):140-149. eLIBRARY ID: 12858377 EDN: KVjwRP</mixed-citation><mixed-citation xml:lang="en">Kozlov I.G., Timakov M.A. Immunotherapy: yesterday, today, tomorrow. Pediatriya. Zhurnal im G.N. Speranskogo. 2009;87(4):140-149. (In Russ.) eLIBRARY ID: 12858377 EDN: KVjwRP</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Khaitov R.M. Immunomodulators: myths and reality. Immunologiya. 2020;41(2):101-106. (In Russ.) https://doi.org/10.33029/0206-4952-2020-41-2-101-106</mixed-citation><mixed-citation xml:lang="en">Khaitov R.M. Immunomodulators: myths and reality. Immunologiya. 2020;41(2):101-106. (In Russ.) https://doi.org/10.33029/0206-4952-2020-41-2-101-106</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guryanova SV, Khaitov RM. Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine. Front Immunol. 2021;12:607178. https://doi.org/10.3389/ﬁmmu.2021.607178</mixed-citation><mixed-citation xml:lang="en">Guryanova SV, Khaitov RM. Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine. Front Immunol. 2021;12:607178. https://doi.org/10.3389/ﬁmmu.2021.607178</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gudyrev OS, Andronova TM, Nesterova EI. The results of the study of the carcinogenic properties of glucosaminylmuramyldipeptide GMDP in chronic experiments in mice and rats. Research Results in Pharmacology. 2018;4(4):97–106. https://doi.org/10.3897/rrpharmacology.4.32191</mixed-citation><mixed-citation xml:lang="en">Gudyrev OS, Andronova TM, Nesterova EI. The results of the study of the carcinogenic properties of glucosaminylmuramyldipeptide GMDP in chronic experiments in mice and rats. Research Results in Pharmacology. 2018;4(4):97–106. https://doi.org/10.3897/rrpharmacology.4.32191</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Половинкина В.С., Марков Е.Ю. Иммуноадъювантные свойства мурамилдипептида. Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук. 2012;83(1):149-153. eLIBRARY ID: 17902836 EDN: PBTYwD</mixed-citation><mixed-citation xml:lang="en">Polovinkina V.S., Markov E.Y. Structure and adjuvanticity immune properties of muramyldipeptide. BULLETIN OF THE All-Russian Scientiﬁc Research CENTER OF THE Russian Academy OF Sciences. 2012;83(1):149-153. (In Russ.) eLIBRARY ID: 17902836 EDN: PBTYwD</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ушкалова Е.А., Зырянов С.К., Затолочина К.Э. Соединения на основе мурамилпептидов в современной медицине: фокус на глюкозаминилмурамилдипептид. Терапевтический архив. 2019;91(12):122-127. https://doi.org/10.26442/00403660.2019.12.000471</mixed-citation><mixed-citation xml:lang="en">Ushkalova E.A., Zyryanov S.K., Zatolochina K.E. Muramyldipeptide – based compounds in current medicine: focus on glucosaminylmuramyl dipeptide. Terapevticheskii arkhiv. 2019;91(12):122-127. (In Russ.) https://doi.org/10.26442/00403660.2019.12.000471</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Крашенинников А.Е., Матвеев А.В., Андронова Т.М., Гурьянова С.В., Шилова Н.В., Козлов И.Г. Безопасность применения препарата «Ликопид®» по мнению врачей различных специальностей. Пермский медицинский журнал (сетевое издание "Perm medical journal"). 2019;36(2):81-92. https://doi.org/10.17816/pmj36281-92</mixed-citation><mixed-citation xml:lang="en">Krasheninnikov A.E., Matveev A.V., Andronova T.M., Guryanova S.V., Shilova N.V., Kozlov I.G. Safety of using the preparation “Licopid®” in opinion of experts in various specialities. Perm Medical Journal. 2019;36(2):81-92. https://doi.org/10.17816/pmj36281-92</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Абдулгусенова К.А., Алиева М.У., Врубель М.Е., Гусейнов А.К., Струговщик Ю.С. Клиническая фармакология ликопида. Успехи современного естествознания. 2014;11-3:126-127. eLIBRARY ID: 22373762 EDN: SVPSVB</mixed-citation><mixed-citation xml:lang="en">Abdulguseynova K.A., Alieva M.U., Vrubel M.E., Huseynov A.K., Strugovschik Y.S. Clinical pharmacology of lycopene. The successes of modern natural science. 2014;11-3:126-127. (In Russ.) eLIBRARY ID: 22373762 EDN: SVPSVB</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Каннер Е.В., Горелов А.В., Печкуров Д.В., Горелова Е.А., Максимов М.Л., Ермолаева А.С. Мукозальная иммунная система пищеварительного и респираторного трактов: возможности профилактики и лечения инфекционных заболеваний. Медицинский Совет. 2019;(11):100-107. https://doi.org/10.21518/2079-701x-2019-11-100-107</mixed-citation><mixed-citation xml:lang="en">Kanner E.V., Gorelov A.V., Pechkurov D.V., Gorelova E.A., Maksimov M.L., Ermolaeva A.S. Mucosal immune system of digestive and respiratory tracts: possibilities of prevention and treatment of infectious diseases. Meditsinskiy sovet = Medical Council. 2019;(11):100-107. (In Russ.) https://doi.org/10.21518/2079-701x-2019-11-100-107</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mukherjee T, Hovingh ES, Foerster EG, Abdel-Nour M, Philpott Dj, Girardin SE. NOD1 and NOD2 in inﬂammation, immunity and disease. Arch Biochem Biophys. 2019;670:69-81. https://doi.org/10.1016/j.abb.2018.12.022</mixed-citation><mixed-citation xml:lang="en">Mukherjee T, Hovingh ES, Foerster EG, Abdel-Nour M, Philpott Dj, Girardin SE. NOD1 and NOD2 in inﬂammation, immunity and disease. Arch Biochem Biophys. 2019;670:69-81. https://doi.org/10.1016/j.abb.2018.12.022</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tsukidate T, Hespen Cw, Hang HC. Small molecule modulators of immune pattern recognition receptors. RSC Chem Biol. 2023;4(12):1014-1036. https://doi.org/10.1039/d3cb00096f</mixed-citation><mixed-citation xml:lang="en">Tsukidate T, Hespen Cw, Hang HC. Small molecule modulators of immune pattern recognition receptors. RSC Chem Biol. 2023;4(12):1014-1036. https://doi.org/10.1039/d3cb00096f</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Laman AG, Lathe R, Shepelyakovskaya AO, Gartseva A, Brovko FA, et al. Muramyl peptides activate innate immunity conjointly via YB1 and NOD2. Innate Immun. 2016;22(8):666-673. https://doi.org/10.1177/1753425916668982</mixed-citation><mixed-citation xml:lang="en">Laman AG, Lathe R, Shepelyakovskaya AO, Gartseva A, Brovko FA, et al. Muramyl peptides activate innate immunity conjointly via YB1 and NOD2. Innate Immun. 2016;22(8):666-673. https://doi.org/10.1177/1753425916668982</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y, Song F, jiang H, Nuñez G, Smith DE. SLC15A2 and SLC15A4 Mediate the Transport of Bacterially Derived Di/ Tripeptides To Enhance the Nucleotide-Binding Oligomerization Domain-Dependent Immune Response in Mouse Bone Marrow-Derived Macrophages. J Immunol. 2018;201(2):652-662. https://doi.org/10.4049/jimmunol.1800210</mixed-citation><mixed-citation xml:lang="en">Hu Y, Song F, jiang H, Nuñez G, Smith DE. SLC15A2 and SLC15A4 Mediate the Transport of Bacterially Derived Di/ Tripeptides To Enhance the Nucleotide-Binding Oligomerization Domain-Dependent Immune Response in Mouse Bone Marrow-Derived Macrophages. J Immunol. 2018;201(2):652-662. https://doi.org/10.4049/jimmunol.1800210</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Girardin SE, Boneca IG, Carneiro LA, Antignac A, jéhanno M, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. 2003;300(5625):1584-1587. https://doi.org/10.1126/science.1084677</mixed-citation><mixed-citation xml:lang="en">Girardin SE, Boneca IG, Carneiro LA, Antignac A, jéhanno M, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. 2003;300(5625):1584-1587. https://doi.org/10.1126/science.1084677</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Viala ja, Sansonetti P, Philpott Dj. Nods and 'intracellular' innate immunity. C R Biol. 2004;327(6):551-555. https://doi.org/10.1016/j.crvi.2004.02.010</mixed-citation><mixed-citation xml:lang="en">Viala ja, Sansonetti P, Philpott Dj. Nods and 'intracellular' innate immunity. C R Biol. 2004;327(6):551-555. https://doi.org/10.1016/j.crvi.2004.02.010</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mulder wjM, Ochando j, joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18(7):553-566. https://doi.org/10.1038/s41573-019-0025-4</mixed-citation><mixed-citation xml:lang="en">Mulder wjM, Ochando j, joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18(7):553-566. https://doi.org/10.1038/s41573-019-0025-4</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Petnicki-Ocwieja T, Hrncir T, Liu Yj, Biswas A, Hudcovic T, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A. 2009;106(37):15813-15818. https://doi.org/10.1073/pnas.0907722106</mixed-citation><mixed-citation xml:lang="en">Petnicki-Ocwieja T, Hrncir T, Liu Yj, Biswas A, Hudcovic T, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A. 2009;106(37):15813-15818. https://doi.org/10.1073/pnas.0907722106</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Geddes K, Magalhães jG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009;8(6):465-479. https://doi.org/10.1038/nrd2783</mixed-citation><mixed-citation xml:lang="en">Geddes K, Magalhães jG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009;8(6):465-479. https://doi.org/10.1038/nrd2783</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sirard jC, Vignal C, Dessein R, Chamaillard M. Nod-like receptors: cytosolic watchdogs for immunity against pathogens. PLoS Pathog. 2007;3(12):e152. https://doi.org/10.1371/journal.ppat.0030152</mixed-citation><mixed-citation xml:lang="en">Sirard jC, Vignal C, Dessein R, Chamaillard M. Nod-like receptors: cytosolic watchdogs for immunity against pathogens. PLoS Pathog. 2007;3(12):e152. https://doi.org/10.1371/journal.ppat.0030152</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Irazoki O, Hernandez SB, Cava F. Peptidoglycan Muropeptides: Release, Perception, and Functions as Signaling Molecules. Front Microbiol. 2019;10:500. https://doi.org/10.3389/fmicb.2019.00500</mixed-citation><mixed-citation xml:lang="en">Irazoki O, Hernandez SB, Cava F. Peptidoglycan Muropeptides: Release, Perception, and Functions as Signaling Molecules. Front Microbiol. 2019;10:500. https://doi.org/10.3389/fmicb.2019.00500</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Мещерякова Е.А, Андронова Т.М., Иванов В.Т. Сигнальные клеточные пути и белковые взаимодействия, индуцированные мурамоилпептидами (обзорная статья). Биоорганическая химия. 2010;36(5):1-15. https://doi.org/10.1134/S1068162010050018</mixed-citation><mixed-citation xml:lang="en">Meshcheryakova E.A., Andronova T.M., Ivanov V.T. Protein interaction network and signaling pathways activated by muramyl peptides. Russian Journal of Bioorganic Chemistry. 2010;36(5);535-549. https://doi.org/10.1134/S1068162010050018</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Караулов А.В., Калюжини О.В. Иммунотерапия инфекционных болезней: проблемы и перспективы. Терапевтический архив. 2013;11:100-108. eLIBRARY ID: 21085880 EDN: RTKZHV</mixed-citation><mixed-citation xml:lang="en">Karaulov A.V., Kalyuzhin O.V. Immunotherapy for infectious diseases: challenges and prospects. Therapeutic Archive. 2013;11:100-108. (In Russ.) eLIBRARY ID: 21085880 EDN: RTKZHV</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Гурьянова С.В., Кудряшова Н.А., Катаева А.А., Орозбекова Б.Т., Колесникова Н.В., Чучалин А.Г. Современные методы увеличения сопротивляемости острым респираторным инфекциям. Вестник Российского университета дружбы народов. Серия: Медицина. 2021;25(3):181-195. https://doi.org/10.22363/2313-0245-2021-25-3-181-195</mixed-citation><mixed-citation xml:lang="en">Guryanova S.V., Kudryashova N.A., Kataeva A.A., Orozbekova B.T., Kolesnikova N.V., Chuchalin A.G. Novel approaches to increase resistance to acute respiratory infections. RUDN Journal of Medicine. 2021;25(3):181-195. https://doi.org/10.22363/2313-0245-2021-25-3-181-195</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Кабденова А.Т., Сатыбалдиева ж.А. Квантовохимический анализ структуры Ликопида и уровень экспрессии CD маркеров. Альманах современной науки и образования. 2010;(9):67-70. eLIBRARY ID: 17342393 EDN: OPNCHD</mixed-citation><mixed-citation xml:lang="en">Kabdenova A.T., Satybaldieva j.A. quantum chemical analysis of the structure of Lycopene and the expression level of CD markers. Almanac of modern science and Education. 2010;(9):67-70. (In Russ.) eLIBRARY ID: 17342393 EDN: OPNCHD</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Гурьянова С.В., Хаитов Р.М. Глюкозаминилмурамилдипептид в терапии и профилактике инфекционных заболеваний. Инфекционные болезни: новости, мнения, обучение. 2020;9(3):79-86. https://doi.org/10.33029/2305-3496-2020-9-3-79-86.</mixed-citation><mixed-citation xml:lang="en">Guryanova S.V., Khaitov R.M. Glucosaminylmuramyldipeptide in the therapy and prevention of infectious diseases. Infectious diseases: news, opinions, training. 2020; 9(3):79-86. (In Russ.) https://doi.org/10.33029/2305-3496-2020-9-3-79-86.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Е.В. ГМДП (Ликопид) в снижении сезонной заболеваемости у взрослых (данные слепого плацебоконтролируемого исследования). Практическая медицина. Оториноларингология. Аллергология. Пульмонология. 2011;48(1):2-4.</mixed-citation><mixed-citation xml:lang="en">Voronina E.V. GMDP (Liсopid) in reducing the seasonal morbidity in adults (data of blind, placebocontrolled study). Practical medicine. Otorhinolaryngology. Allergology. Pulmonology. 2011;48(1):2-4. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Зурочка В.А., Забков О.И., Добрынина М.А., Гриценко В.А., Давыдова Е.В., и др. Иммунологические критерии эффективности комплексной этиопатогенетической терапии у больных хронической вирусной инфекцией, ассоциированной с вирусом Эпштейна–Барр. Инфекция и иммунитет. 2020;10(2):338-346. https://doi.org/10.15789/2220-7619-CDC-1141</mixed-citation><mixed-citation xml:lang="en">Zurochka V.A., Zabkov O.I., Dobrynina M.A., Gritsenko V.F., Davydova E.V., et al. Clinical diagnostic criteria of eﬃciency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection. Russian Journal of Infection and Immunity. 2020;10(2):338-346. https://doi.org/10.15789/2220-7619-CDC-1141</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Стагниева И.В., Симбирцев А.С. Эффективность иммуномодулирующей терапии у больных риносинуситом. Медицинская иммунология. 2015;17(5):423-430. https://doi.org/10.15789/1563-0625-2015-5-423-430</mixed-citation><mixed-citation xml:lang="en">Stagnieva I.V., Simbirtsev A.S. Immunotherapy eﬃciency in rhinosinusitis patients. Medical Immunology (Russia). 2015;17(5):423-430. (In Russ.) https://doi.org/10.15789/1563-0625-2015-5-423-430</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Земскова В.А., Земсков А.М., Земсков В.М., Золоедов В.И. Актуальные проблемы иммунотерапии гнойновоспалительных заболеваний. Российский медицинский журнал. 2016;22(2):70-74. https://doi.org/10.18821/0869-2106-2016-22-2-70-74</mixed-citation><mixed-citation xml:lang="en">Zemskova V.A., Zemskov A.M., Zemskov V.M., Zoloedov V.I. The actual problems of immune therapy of pyo-inﬂammatory diseases. Russian Medicine. 2016;22(2):70-74. https://doi.org/10.18821/0869-2106-2016-22-2-70-74</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Перова М.В., Кузнецова Р.Н., Бацунов О.К., Тотолян А.А. Оценка эффективности применения ликопида при анализе показателей иммунного статуса пациентов хроническим рецидивирующим фурункулезом. Иммунологические проблемы в хирургии. 2017;19:232-233. eLIBRARY ID: 29758368 EDN: ZBFGOD</mixed-citation><mixed-citation xml:lang="en">Perova M.V., Kuznetsova R.N., Batsunov O.K., Totolyan A.A. Evaluation of the eﬀectiveness of the use of lycopide in the analysis of indicators of the immune status of patients with chronic recurrent furunculosis. Immunological problems in surgery. 2017;19:232-233. (In Russ.) eLIBRARY ID: 29758368 EDN: ZBFGOD</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Цывкина Е.А., Феденко Е.С., Будихина А.С., Пинегин Б.В. Влияние иммунотропной терапиина уровень a-дефензинов в нейтрофилахпериферической крови у больныхпиодермией. Российский Аллергологический Журнал. 2010;7(6):25-30. https://doi.org/10.36691/RjA881</mixed-citation><mixed-citation xml:lang="en">Tsyvkina E.A., Fedenko E.S., Budikhina A.S., Pinegin B.V. Immune therapy inﬂuence on a-defensin level in peripheral blood neutrophiles in pyodermia patients. Russian Journal of Allergy. 2010;7(6):25-30. (In Russ.) https://doi.org/10.36691/RjA881</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Песчаный В.Г. Роль иммуномодуляторов в консервативном лечении детей с хроническим тонзиллитом. Национальное здоровье. 2020;2:35-38. eLIBRARY ID: 43142238 EDN: EHOxNE</mixed-citation><mixed-citation xml:lang="en">Peschany V.G. The role of immunomodulators in the conservative treatment of children with chronic tonsillitis. National health. 2020;2:35-38. (In Russ.) eLIBRARY ID: 43142238 EDN: EHOxNE</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Милютина Л.Н., Голубев А.О. Опыт применения Ликопида для санации постинфекционного сальмонеллезного бактерионосительства у детей. Российский вестник перинатологиии педиатрии. 2015;4:100–108. eLIBRARY ID: 24336899 EDN: UMORHT</mixed-citation><mixed-citation xml:lang="en">Milutina L.N., Golubev A.O. The experience of using Lycopene for the rehabilitation of post-infectious salmonella bacteriocarriage in children. Russian Bulletin of Perinatology of Pediatrics. 2015;4:100–108. (In Russ.) eLIBRARY ID: 24336899 EDN: UMORHT</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Гурьянова С.В., Хаитов РМ. Глюкозаминилмурамилдипептид - ГМДП: воздействие на мукозальный иммунитет (к вопросу иммунотерапии и иммунопрофилактики). Иммунология. 2020;41(2):174-183. https://doi.org/10.33029/0206-4952-2020-41-2-174-183</mixed-citation><mixed-citation xml:lang="en">Guryanova S.V, Khaitov R.M. Glucosaminylmuramyldipeptide - GMDP: eﬀect on mucosal immunity (on the issue of immunotherapy and immunoprophylaxis). Immunologiya. 2020;41(2):174-183. (in Russ.) https://doi.org/10.33029/0206-4952-2020-41-2-174-183</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Жаркова О.А. Эффективность иммунокорригирующей терапии при хроническом периодонтите. Стоматолог. Минск. 2020;3(38):60-67. https://doi.org/10.32993/dentist.20.3(38).3</mixed-citation><mixed-citation xml:lang="en">Zharkova O.A. The eﬀectiveness of immunocorrective therapy in chronic periodontitis. Dentist. Minsk. 2020;3(38):60-67. (In Russ.) https://doi.org/10.32993/dentist.20.3(38).3</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Малявин. А.Г. Обзор возможностей использования препарата Ликопид в пульмонологической и фтизиатрической практике. Терапия. 2020;5:174-186. https://doi.org/10.18565/therapy.2020.5.174-186</mixed-citation><mixed-citation xml:lang="en">Malyavin. A.G. Review of the possibilities of using the drug Lycopid in pulmonological and phthisiological practice. Therapy. 2020;5:174-186. (In Russ.) https://doi.org/10.18565/therapy.2020.5.174-186</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Скиба Т.А. Эффективность ГМДП в иммунореабилитации больных хронической обструктивной болезнью легких, ассоциированной с остеоартрозом. Врач-аспирант. 2017;3(82):46-51. eLIBRARY ID: 29060817 EDN: YLYjTH</mixed-citation><mixed-citation xml:lang="en">Skiba T.A. The eﬀectiveness of GMDP in immunorehabilitation of patients with chronic obstructive pulmonary disease associated with osteoarthritis. Postgraduate doctor. 2017;3 (82):46-51. (In Russ.) eLIBRARY ID: 29060817 EDN: YLYjTH</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Макацария А.Д., Бицадзе В.О., Хизроева Д.Х., Викулов Г.Х., Гомберг М.А., Хрянин А.А. Эффективность и безопасность глюкозаминилмурамилдипептида в лечении заболеваний, ассоциированных с вирусом папилломы человека: систематический обзор. Акушерство, Гинекология и Репродукция. 2019;13(2):132-154. https://doi.org/10.17749/2313-7347.2019.13.2.132-154</mixed-citation><mixed-citation xml:lang="en">Makatsariya A.D., Bitsadze V.O., Khizroeva j.Kh., Vikulov G. Kh., Gomberg M.A., Khryanin A.A. Eﬃcacy and safety of glucosaminylmuramyl dipeptide in treatment of human papillomavirus-associated diseases: a systematic review. Obstetrics, Gynecology and Reproduction. 2019;13(2):132-154. https://doi.org/10.17749/2313-7347.2019.13.2.132-154</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Гурьянова С.В., Колесникова Н.В., Гудима Г.О., Лежава Н.Л., Караулов А.В. Динамика иммунологических и микробиологических показателей ротовой жидкости при терапии кариеса. Иммунология. 2021;42(4):386-394. https://doi.org/10.33029/0206-4952-2021-42-4-386-394</mixed-citation><mixed-citation xml:lang="en">Guryanova S.V., Kolesnikova N.V., Gudima G.O., Lezhava N.L., Karaulov A.V. Dynamics of immunological and microbiological indicators of oral ﬂuid in caries therapy. Immunologiya. 2021;42(4):386-394. (In Russ.) https://doi.org/10.33029/0206-4952-2021-42-4-386-394</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Palache AM, Beyer wE, Hendriksen E, Gerez L, Aston R, et al. Adjuvancy and reactogenicity of N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent inﬂuenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents. Vaccine. 1996;14(14):1327-1330. https://doi.org/10.1016/s0264-410x(96)00075-8</mixed-citation><mixed-citation xml:lang="en">Palache AM, Beyer wE, Hendriksen E, Gerez L, Aston R, et al. Adjuvancy and reactogenicity of N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent inﬂuenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents. Vaccine. 1996;14(14):1327-1330. https://doi.org/10.1016/s0264-410x(96)00075-8</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Соболева Н.Г., Шаповалова Т.И., Осипова И.Г. Результаты двойного слепого рандомизированного исследования клинической эффективности ликопида в комплексном лечении цитомегаловирусного гепатита у детей. Педиатрия: научно-практический журнал. 2009;87(2):100-103. eLIBRARY ID: 12859999 EDN: KVKURL</mixed-citation><mixed-citation xml:lang="en">Soboleva NG, Shapovalova TI, Osipova IG. Results of double-blind randomized study of clinical eﬃcacy of Licopid in complex treatment of cytomegalovirus hepatitis in children. Pediatriya: nauchno-prakticheskij zhurnal. 2009;87(2):100-103 (In Russ.). eLIBRARY ID: 12859999 EDN: KVKURL</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Конорев М.Р. Применение иммуномодулятора ликопида при проведении антихеликобактерной терапии первого выбора. Иммунопатология, аллергология, инфектология. 2012;1:45–50. eLIBRARY ID: 21165788 EDN: RVELjR</mixed-citation><mixed-citation xml:lang="en">Konorev M.R. The use of the immunomodulator lycopide during the ﬁrst-choice antichelicobacter therapy. Immunopathology, allergology, and infectology. 2012;1:45–50. (In Russ.) eLIBRARY ID: 21165788 EDN: RVELjR</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Грудянов А.И., Фоменко Е.В., Калюжин О.В. Антибактериальный эффект иммуномодулятора на основе композиции мурамилпептидов при хроническом генерализованном пародонтите. Стоматология. 2021;100(4):16-19. https://doi.org/10.17116/stomat202110004116</mixed-citation><mixed-citation xml:lang="en">Grudyanov AI, Fomenko EV, Kalyuzhin OV. Antibacterial eﬀect of a non-speciﬁc immunomodulator based on muramilpeptides in chronic periodontitis. Stomatology. 2021;100(4):16-19. (In Russ.) https://doi.org/10.17116/stomat202110004116</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Жукова С.И., Хабарова И.А., Топорков А.В., Викторов Д.В., Агеева Н.П., Сенина Т.В. Совершенствование экстренной профилактики и лечения опасных инфекций с помощью иммуномодуляторов. Астраханский медицинский журнал. 2019;14(3):20-36. https://doi.org/10.17021/2019.14.3.20.36</mixed-citation><mixed-citation xml:lang="en">Zhukova S.I., Khabarova I.A., Toporkov A.V., Victorov D.V., Ageeva N.P., Senina T.V. Improving emergency prevention and treatment of dangerous infections using immunomodulators. Astrakhan medical journal. 2019;14(3):20-36. (In Russ.) https://doi.org/10.17021/2019.14.3.20.36</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Баринский И.Ф., Лазаренко А.А., Алимбарова Л.М. Изучение эффективности использования отечественных иммуномодуляторов, а также их сочетанного действия со специфическими вакцинами при экспериментальных арбовирусных инфекциях. Иммунология. 2012;4:181-183. eLIBRARY ID: 18756125 EDN: PULLMF</mixed-citation><mixed-citation xml:lang="en">Barinsky I.F., Lazarenko A.A., Alimbarova L.M. The study of the eﬀectiveness of the use of domestic immunomodulators, as well as their combined action with speciﬁc vaccines in experimental arbovirus infections. Immunology. 2012;4:181-183. (In Russ.) eLIBRARY ID: 18756125 EDN: PULLMF</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Баринский И.Ф., Алибарова Л.М, Лазаренко А.А., Давыдова А.А. Иммуномодуляторы и специфические инактивированные вакцины в экстренной профилактике экспериментальных арбовирусных инфекций. Вопросы вирусологии. 2013;58(4):35. eLIBRARY ID: 20502316 EDN: RGqYSD</mixed-citation><mixed-citation xml:lang="en">Barinsky I.F., Alimbarova L.M., Lazarenko A.A., Davydova A.A. Immunomodulators and speciﬁc inactivated vaccines in the emergency prevention of experimental arbovirus infections. Questions of virology. 2013;58(4):35. (In Russ.) eLIBRARY ID: 20502316 EDN: RGqYSD</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Богачева Н.В., Охапкина В.Ю., Пяткова Н.В., Федотов А.К., Кучеренко А.С. Экспериментальное изучение влияния иммуномодуляторов на эффективность применения вакцины бруцеллезной живой сухой. Эпидемиология и Вакцинопрофилактика. 2016;15(2):84-92. https://doi.org/10.31631/2073-3046-2016-15-2-84-92</mixed-citation><mixed-citation xml:lang="en">Bogacheva N.V., Okhapkina V.Y., Pyatkova N.V., Fedotov A.K., Kucherenko A.S. Experimental Research of the Inﬂuence of Immunomodulators on Eﬃciency Using of Brucellosis Living Dry Vaccine. Epidemiology and Vaccinal Prevention. 2016;15(2):84-92. (In Russ.) https://doi.org/10.31631/2073-3046-2016-15-2-84-92</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Филиппенко А.В., Иванова И.А., Омельченко Н.Д., Труфанова А.А. Влияние иммуномодуляторов на формирование поствакцинального противохолерного иммунитета. Журнал микробиологии, эпидемиологии и иммунобиологии. 2022;99(1):81-92. https://doi.org/10.36233/0372-9311-188</mixed-citation><mixed-citation xml:lang="en">Filippenko A.V., Ivanova I.A., Omelchenko N.D., Trufanova A.A. The inﬂuence of immunomodulators on the formation of vaccine-induced cholera immunity. Journal of microbiology, epidemiology and immunobiology. 2022;99(1):81-92. https://doi.org/10.36233/0372-9311-188</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Филиппенко А.В., Омельченко Н.Д., Пасюкова Н.И., Труфанова А.А., Иванова И.А. Совершенствование специфической профилактики холеры с помощью иммуномодуляторов. Медицинская иммунология. 2021;23(4):915-920. https://doi.org/10.15789/1563-0625-IOS-2248</mixed-citation><mixed-citation xml:lang="en">Filippenko A.V., Omelchenko N.D., Pasyukova N.I., Trufanova A.A., Ivanova I.A. Improvement of speciﬁc cholera prevention using immunomodulators. Medical Immunology (Russia). 2021;23(4):915-920. https://doi.org/10.15789/1563-0625-IOS-2248</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
